. Author manuscript; available in PMC: 2010 Sep 1.

Published in final edited form as: Toxicol Appl Pharmacol. 2009 Jun 16;239(2):200–207. doi: 10.1016/j.taap.2009.06.007

Table 4.

The effects of AS3MT polymorphisms on the distribution of As metabolites in urine according the presence of As-skin lesions.

SNPs Allelic (n)	% iAs^lll+V	% MAs^lll+V	% DMAs^lll+V	MAs^lll+V/iAs^lll+V	DMAs^lll+V/MAs^lll+V	% iAs^lll	% MAs^lll	% DMAs^lll	% iAs^V	% MAs^V	% DMAs^V
A-477G
Non-skin lesions
A(21)	18.0	11.4	70.6	0.74	8.6	8.1	7.6	47	9.9	3.8	23.5
G(29)	18.4	9.9^*	71.7	0.74	10.5^**	8.9	7.3	46.4	9.5	2.6^*	25.2
As skin lesions
A(26)	16.0	12.2	71.8	0.84	6.8	7.3	7.8	47.4	8.7	4.3	24.4
G(43)	15.9	10.4^**	73.7	0.72	9.4^**	7.5	7.9	50.8	8.4	2.4^**	22.8
Met287Thr
Non-skin lesions
T(47)	17.4	10.0	72.6	0.75	10.3	8.4	6.9	49	9.0	3.0	23.6
C(4)	25.6^*	16.1^**	58.3^*	0.63	4.6^*	9.4	13.0^**	25.6^*	16.2	3.1	32.7
As skin lesions
T(60)	15.8	10.5	73.6	0.76	8.7	8.1	7.3	50.0	8.1	3.2	23.5
C(11)	19.1	15.3^**	65.5^*	0.81	6.6^*	12.3^**	12.7^**	40.9	12.4^*	2.6	24.5
T35587C
Non-skin lesions
T(30)	18.4	11.0	70.6	0.70	9.5	8.3	7.7	48.6	10.1	3.3	22.0
C(21)	17.6	9.7	72.6	0.79	10.3	8.7	7.0	45.1	8.9	2.7	27.5
As skin lesions
T(41)	17.5	12.1	70.4	0.72	7.7	7.8	9.2	46.9	9.7	2.9	23.4
C(30)	14.8^*	10.0^*	75.1^*	0.83	9.5^*	7.3	6.6^*	51.0	7.5^*	3.5	24.1

Student t-test.

Significance is shown in footnote of corresponding tables (p<0.05).

p<0.1.

^**

p<0.05.